Effect of 5-ALA-PDT on VEGF and PCNA expression in human NPC-bearing nude mice

Oncology Reports

Volumn 22, Issue 6, 2009, Pages 1365-1371

  Xie, Ying ^a   Wei, Zheng Bo ^a   Zhang, Zhe ^a   Wen, Wensheng ^a   Huang, Guang Wu ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

5 aminolevulinic acid (5 ALA); Nasopharyngeal carcinoma; PCNA; Photodynamic therapy; VEGF

Indexed keywords

AMINOLEVULINIC ACID; CYCLINE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; HUMAN; HUMAN CELL; IRRADIATION; MALE; METASTASIS; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; NUDE MOUSE; PATHOGENESIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR RECURRENCE; TUMOR VOLUME;

AMINOLEVULINIC ACID; ANIMALS; CARCINOMA; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM TRANSPLANTATION; PHOTOCHEMOTHERAPY; PROLIFERATING CELL NUCLEAR ANTIGEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70449403471     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000576     Document Type: Article

References (33)

1. Shu CH, Shiau CY, Chi KH, Yen SH and Li WY: Salvage surgery for recurrent nasopharyngeal carcinoma in anterior marginal miss after radiotherapy. Otolaryngol Head Neck Surg 121: 622-626, 1999.
2. Wei WI and Sham JS: Nasopharyngeal carcinoma. Lancet 365: 2041-2054, 2005.
3. Cheli R, Addis F, Mortellaro CM, Fonda D, Andreoni A and Cubeddu R: Hematoporphyrin derivative photochemotherapy of spontaneous animal tumors: clinical results with optimized drug dose. Cancer Lett 23: 61-66, 1984.
4. Cheli R, Addis F, Mortellaro CM, Fonda D and Cubeddu R: Photodynamic therapy of spontaneous animal tumors using the active component of hematoporphyrin derivative (DHE) as photosensitizing drug: clinical results. Cancer Lett 38: 101-105, 1987.
5. Dougherty TJ, Gomer CJ, Henderson BW, et al: Photodynamic therapy. J Natl Cancer Inst 90: 889-905, 1998.
6. Brown SB, Brown EA and Walker I: The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 5: 497-508, 2004.
7. Zhao SP, Tao ZD, Xiao JY, Peng YY, Yang YH, Zeng QS and Liu ZW: Clinical use of hematoporphyrin derivative and photoradiation therapy in nasopharyngeal carcinoma. Chin Med J (Engl) 101: 86-91, 1988.
8. Tong MC, van Hasselt CA and Woo JK: Preliminary results of photodynamic therapy for recurrent nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 253: 189-192, 1996.
9. Wang CP, Chang YL, Chen CT, Yang TH and Lou PJ: Photodynamic therapy with topical 5-aminolevulinic acid as a postoperative adjuvant therapy for an incompletely resected primary nasopharyngeal papillary adenocarcinoma: a case report. Lasers Surg Med 38: 435-438, 2006.
10. Lisnjak IO, Kutsenok VV, Polyschuk LZ, Gorobets OB and Gamaleia NF: Effect of photodynamic therapy on tumor angiogenesis and metastasis in mice bearing Lewis lung carcinoma. Exp Oncol 27: 333-335, 2005.
11. Regula J, MacRobert AJ, Gorchein A, et al: Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX, a pilot study. Gut 36: 67-75, 1995.
12. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky KE and Nesland JM: 5-Aminolevulinic acid-based photo-dynamic therapy. Clinical research and future challenges. Cancer 79: 2282-2308, 1997.
13. Yanase S, Nomura J, Matsumura Y, Nagata T, Fujii T and Tagawa T: Synergistic interaction of 5-aminolevulinic acid-based photodynamic therapy with simultaneous hyperthermia in an osteosarcoma tumor model. Int J Oncol 29: 365-373, 2006.
14. Momma T, Hamblin MR, Wu HC and Hasan T: Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res 58: 5425-5431, 1998.
15. Tanaka M, Kubo O, Tajika Y, Takahashi T, Suzuki S and Takakura K: Immunohistochemical evaluation of intracranial recurrent meningiomas: correlation of topoisomerase II alpha expression and cell proliferative potential. No To Shinkei 51: 1033-1039, 1999.
16. Mathews MB, Bernstein RM, Franza BR Jr and Garrels JI: Identity of the proliferating cell nuclear antigen and cyclin. Nature 309: 374-376, 1984.
17. Wang LF, Chai CY, Kuo WR, Tai CF, Lee KW and Ho KY: The prognostic value of proliferating cell nuclear antigen (PCNA) and p53 protein expression in patients with advanced nasopharyngeal carcinoma. Acta Otolaryngol 126: 769-774, 2006.
18. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K and Ludwig H: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71: 2454-2460, 1993.
19. Gomer CJ, Ferrario A and Murphree AL: The effect of localized porphyrin photodynamic therapy on the induction of tumour metastasis. Br J Cancer 56: 27-32, 1987.
20. Schreiber S, Gross S, Brandis A, Harmelin A, Rosenbach-Belkin V, Scherz A and Salomon Y: Local photodynamic therapy (PDT) of rat C6 glioma xenografts with Pd-bacteriopheophorbide leads to decreased metastases and increase of animal cure compared with surgery. Int J Cancer 99: 279-285, 2002.
21. Foultier MT, Vonarx-Coinsmann V, Cordel S, Combre A and Patrice T: Modulation of colonic cancer cell adhesiveness by haematoporphyrin derivative photodynamic therapy. J Photochem Photobiol B 23: 9-17, 1994.
22. Rousset N, Vonarx V, Eleouet S, Carre J, Kerninon E, Lajat Y and Patrice T: Effects of photodynamic therapy on adhesion molecules and metastasis. J Photochem Photobiol B 52: 65-73, 1999.
23. Bates DO and Curry FE: Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway. Am J Physiol 273: H687-H694, 1997.
24. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS and Gomer CJ: Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 60: 4066-4069, 2000.
25. Solban N, Selbo PK, Sinha AK, Chang SK and Hasan T: Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Res 66: 5633-5640, 2006.
26. Ferrario A, Von Tiehl K, Wong S, Luna M and Gomer CJ: Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res 62: 3956-3961, 2002.
27. Peng Q, Warloe T, Moan J, Godal A, Apricena F, Giercksky KE and Nesland JM: Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts. Cancer Res 61: 5824-5832, 2001.
28. Babilas P, Schacht V, Liebsch G, Wolfbeis OS, Landthaler M, Szeimies RM and Abels C: Effects of light fractionation and different fluence rates on photodynamic therapy with 5-aminolaevulinic acid in vivo. Br J Cancer 88: 1462-1469, 2003.
29. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987.
30. Hamm AVeeck JBektas N, et al: Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis. BMC Cancer 8: 25, 2008.
31. Kosharskyy B, Solban N, Chang SK, Rizvi I, Chang Y and Hasan T: A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res 66: 10953-10958, 2006.
32. Mitra S, Cassar SE, Niles DJ, Puskas JA, Frelinger JG and Foster TH: Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1alpha. Mol Cancer Ther 5: 3268-3274, 2006.
33. Zhou Q, Olivo M, Lye KY, Moore S, Sharma A and Chowbay B: Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer Chemother Pharmacol 56: 569-577, 2005.